Gibbs Wealth Management Purchases Shares of 8,131 Bio-Techne Corp $TECH

Posted by Geri Gentry on Jul 26th, 2026

Gibbs Wealth Management bought a new position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,131 shares of the biotechnology company’s stock, valued at approximately $425,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Cetera Investment Advisers lifted its holdings in shares of Bio-Techne by 18.0% during the first quarter. Cetera Investment Advisers now owns 38,797 shares of the biotechnology company’s stock valued at $2,028,000 after purchasing an additional 5,906 shares during the last quarter. First Citizens Bank & Trust Co. boosted its stake in shares of Bio-Techne by 5.0% during the 1st quarter. First Citizens Bank & Trust Co. now owns 5,379 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 255 shares during the period. CI Investments Inc. grew its stake in Bio-Techne by 3.7% in the first quarter. CI Investments Inc. now owns 335,072 shares of the biotechnology company’s stock valued at $17,511,000 after purchasing an additional 12,004 shares in the last quarter. First Trust Advisors LP increased its holdings in Bio-Techne by 2,874.9% in the first quarter. First Trust Advisors LP now owns 1,281,792 shares of the biotechnology company’s stock worth $66,986,000 after buying an additional 1,238,705 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Bio-Techne by 1.7% in the first quarter. PNC Financial Services Group Inc. now owns 93,722 shares of the biotechnology company’s stock worth $4,898,000 after purchasing an additional 1,556 shares in the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Bio-Techne Stock Down 0.2%

Shares of NASDAQ:TECH opened at $71.60 on Friday. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The firm has a market cap of $11.21 billion, a P/E ratio of 103.77, a P/E/G ratio of 8.53 and a beta of 1.29. The company’s 50-day moving average price is $60.48 and its two-hundred day moving average price is $58.82. Bio-Techne Corp has a 12 month low of $43.19 and a 12 month high of $72.16.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The company had revenue of $311.42 million during the quarter, compared to the consensus estimate of $316.11 million. During the same quarter last year, the firm earned $0.56 EPS. The business’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, research analysts forecast that Bio-Techne Corp will post 1.65 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Monday, May 18th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.4%. The ex-dividend date was Monday, May 18th. Bio-Techne’s dividend payout ratio is currently 46.38%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Piper Sandler assumed coverage on Bio-Techne in a research report on Thursday, June 11th. They set a “neutral” rating and a $65.00 target price for the company. Evercore cut Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. TD Cowen cut Bio-Techne from a “buy” rating to a “hold” rating and raised their target price for the stock from $65.00 to $73.00 in a research report on Monday, June 29th. Weiss Ratings upgraded shares of Bio-Techne from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Finally, William Blair cut shares of Bio-Techne from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 25th. Three research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bio-Techne presently has a consensus rating of “Hold” and an average price target of $68.08.

View Our Latest Stock Analysis on Bio-Techne

About Bio-Techne

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.